Phospholipase A2
10 drugs PainImmunologyMetabolic
9
approved indications
10
Approved Drugs
8
Companies
18
Indications
3
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (8 companies)
✓ All 10 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (18 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
BAUSCH AND LOMB 2 drugs
ALIMERA SCIENCES INC 2 drugs
ALEMBIC 1 drug
By Therapeutic Area
Other 5 drugs
Pain 3 drugs
Drugs by Company PRO
ALEMBIC 1 drug
GALDERMA LABS 1 drug
Cipla 1 drug
Novartis 1 drug
HARROW EYE 1 drug
Merck 1 drug
By Therapeutic Area
Other 5 drugs
LOTEPREDNOL ETABONATE AND TOBRAMYCIN, ZYLET, YUTIQ, ASMANEX TWISTHALER +1 more
Pain 3 drugs
DIFLUPREDNATE, DUREZOL, BYQLOVI
Immunology 1 drugs
CLOBEX
Metabolic 1 drugs
ILUVIEN
Indications Treated
InflammationPainUveitisDermatosesPlaque PsoriasisRosaceaPerioral DermatitisDiabetic Macular EdemaInflammatory Ocular ConditionsBacterial Ocular InfectionAllergic ConjunctivitisSuperficial Punctate KeratitisHerpes Zoster KeratitisIritisCyclitisChronic Anterior UveitisCorneal InjuryAcne Rosacea
All Drugs Targeting Phospholipase A2
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| LOTEPREDNOL ETABONATE AND TOBRAMYCIN Top | ALEMBIC | 2025 | 9 | |
| ZYLET Top | BAUSCH AND LOMB | 2004 | 9 | |
| CLOBEX | GALDERMA LABS | 2003 | 4 | Immunology |
| DIFLUPREDNATE | Cipla | 2021 | 3 | Pain |
| DUREZOL | Novartis | 2008 | 3 | Pain |
| ILUVIEN | ALIMERA SCIENCES INC | 2014 | 2 | Metabolic |
| BYQLOVI | HARROW EYE | 2024 | 2 | Pain |
| YUTIQ | ALIMERA SCIENCES INC | 2018 | 1 | |
| ASMANEX TWISTHALER | Merck | 2005 | 1 | |
| RETISERT | BAUSCH AND LOMB | 2005 | 1 |